Sowell Financial Services’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-11,190
Closed -$18K 3184
2021
Q1
$18K Hold
11,190
﹤0.01% 2107
2020
Q4
$24K Sell
11,190
-44
-0.4% -$104 ﹤0.01% 1668
2020
Q3
$30K Sell
11,234
-100
-0.9% -$359 ﹤0.01% 1389
2020
Q2
$45K Buy
11,334
+8,515
+302% +$16.3K ﹤0.01% 1190
2020
Q1
$2K Hold
2,819
﹤0.01% 2159
2019
Q4
$4K Hold
2,819
﹤0.01% 2029
2019
Q3
$2K Buy
+2,819
New +$1.73K ﹤0.01% 2175
2019
Q1
$9K Buy
+3,274
New +$9.66K ﹤0.01% 572
2018
Q4
Sell
-12,020
Closed -$55K 557
2018
Q3
$55K Buy
12,020
+1,530
+15% +$5.8K 0.01% 361
2018
Q2
$29K Sell
10,490
-4,685
-31% -$24.5K 0.01% 294
2018
Q1
$82K Sell
15,175
-10,157
-40% -$76K 0.02% 267
2017
Q4
$190K Sell
25,332
-9,092
-26% -$76.9K 0.05% 245
2017
Q3
$302K Sell
34,424
-40,949
-54% -$347K 0.08% 199
2017
Q2
$593K Sell
75,373
-2,221
-3% -$22K 0.17% 119
2017
Q1
$714K Sell
77,594
-1,332
-2% -$15.1K 0.21% 107
2016
Q4
$667K Buy
+78,926
New +$1.25M 0.22% 100

Other funds holding NAVB

Sowell Financial Services's NAVB Position: Q2 2021 in Review

Sowell Financial Services sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2021, closing a stake of 11,190 shares — an estimated $18K sold.

Sowell Financial Services first reported a position in NAVB in Q4 2016 and held it in 16 quarters. The position peaked at $714K in Q1 2017. 31 funds tracked by Wall St. Rank hold NAVB as of Q2 2021.

  • Sowell Financial Services reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2021 after selling out during the quarter.
  • Sowell Financial Services sold 11,190 Navidea Biopharmaceuticals Inc. shares in Q2 2021, an estimated $18K.
  • Sowell Financial Services first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2016 and held it in 16 quarters.
  • Sowell Financial Services's Navidea Biopharmaceuticals Inc. position peaked at $714K in Q1 2017.
  • 31 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2021.

Based on Sowell Financial Services's 13F filing for Q2 2021, filed 5 Aug 2021.